Tolerogenic insulin peptide therapy precipitates type 1 diabetes

Bergman, Marie-Louise; Lopes-Carvalho, Thiago; Martins, Ana-Catarina; Grieco, Fabio A.; Eizirik, Décio L.; Demengeot, Jocelyne

http://hdl.handle.net/10400.7/819

Use this identifier to reference this record.

Name:	Description:	Size:	Format:
Demengeot_J.Exp.Med.(2017).pdf	main article	986.24 KB	Adobe PDF	Download
Demengeot_J.Exp.Med.(2017)_SM.pdf	supplementary materials	638.25 KB	Adobe PDF	Download

Send Feedback

Authors

Bergman, Marie-Louise

Lopes-Carvalho, Thiago

Martins, Ana-Catarina

Grieco, Fabio A.

Eizirik, Décio L.

Demengeot, Jocelyne

Abstract(s)

Daniel et al. (https://doi.org/10.1084/jem.20110574) have previously published in JEM a study on the preventive effect of tolerogenic vaccination with a strong agonist insulin mimetope in type 1 diabetes. Our study now challenges these results and shows that osmotic pump delivery of the modified insulin peptide R22E did not prevent hyperglycemia, accelerated disease onset, increased its incidence, and worsened insulitis.

Description

This deposit is composed by the main article plus the supplementary materials of the publication.

Keywords

Autoimmunity diabetes insulin Vaccination

URI

http://hdl.handle.net/10400.7/819

Citation

Tolerogenic insulin peptide therapy precipitates type 1 diabetes Marie-Louise Bergman, Thiago Lopes-Carvalho, Ana-Catarina Martins, Fabio A. Grieco, Décio L. Eizirik, Jocelyne Demengeot Journal of Experimental Medicine Jul 2017, 214 (7) 2153-2156; DOI: 10.1084/jem.20160471